Athira returns home as Ayisha after High Court upholds her right to follow Islam

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Mangaluru, May 12: Two people hailing from Udupi district tested positive for covid-19 today. The sources of this infection is said to be Mangaluru's First Neuro Hospital.

Fresh bulletin from health and family welfare department revealed that a 52-year-old woman and a 26-year-old man from Karkala in Udupi were tested positive for the deadly coronavirus.

Among them, the woman had undergone treatment at the First Neuro Hospital. She is said to have contracted the infection from P-507 who was also was tested positive  April 27. And the youth was in touch with the woman.

The duo have not visited their home in Karkala for past few days. They were in quarantine and tested positive while being admitted at the same hospital.

With this the total number of COVID-19 cases found in Dakshina Kannada district are 33 now. Three among them have died and 14 have been discharged. Now, the district has 16 active coronavirus cases.

Mangaluru, Apr 23: An elderly woman who was tested positive for COVID-19 in Dakshina Kannada district today breathed her last.

The deceased is a 77-year-old woman from Bantwal taluk. 

She is said to be a close relative of the Bantwal woman who died of COVID-19 on April 19.

She was shifted to govt Wenlock Hospital which is now converted into COVID-19 hospital on April 22 from a private hospital.

Her throat swabs were sent for testing. Health and family welfare department earlier today confirmed that she was tested positive for coronavirus.

Within hours she breathed her last without responding to any treatment. 

So far 17 corona positive cases have been confirmed in the district including two deaths. Most of them have returned home after recovering.